Kobayashi Pharmaceuticals Sustainability Profile
Kobayashi Pharmaceuticals Co., Ltd., commonly known as Kobayashi, is a leading player in the pharmaceutical and consumer healthcare industry, headquartered in Japan. Established in 1907, the company has a rich history marked by innovation and growth, with significant operations across Asia and beyond. Kobayashi is renowned for its diverse range of products, including over-the-counter medications, personal care items, and health supplements. Their unique formulations and commitment to quality set them apart in a competitive market. With a strong focus on research and development, Kobayashi has achieved notable milestones, solidifying its position as a trusted name in healthcare. The company continues to excel, leveraging its expertise to meet the evolving needs of consumers, while maintaining a reputation for excellence in product efficacy and safety.
DitchCarbon Score
How does Kobayashi Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kobayashi Pharmaceuticals's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kobayashi Pharmaceuticals's reported carbon emissions
In 2022, Kobayashi Pharmaceuticals reported total greenhouse gas emissions of approximately 551,000,000 kg CO2e, with emissions distributed across various scopes: 6,000,000 kg CO2e for Scope 1, 18,000,000 kg CO2e for Scope 2 (market-based), and 551,000,000 kg CO2e for Scope 3. The total emissions for Scope 1 and 2 combined were about 17,857,000 kg CO2e. Kobayashi Pharmaceuticals has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 51% by 2030, using 2018 as the base year. Additionally, the company targets a 15% reduction in absolute Scope 3 emissions within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support efforts to limit global warming to 1.5°C. The company has demonstrated a commitment to sustainability, with a focus on reducing its carbon footprint across all operational scopes. As of the latest data, Kobayashi Pharmaceuticals is actively working towards these reduction goals, reflecting its dedication to environmental responsibility within the consumer durables and personal products sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | - | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000 |
How Carbon Intensive is Kobayashi Pharmaceuticals's Industry?
How Carbon Intensive is Kobayashi Pharmaceuticals's Location?
Kobayashi Pharmaceuticals's Scope 3 Categories Breakdown
Kobayashi Pharmaceuticals's Scope 3 emissions, which decreased by 100% last year and decreased by approximately 100% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Kobayashi Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kobayashi Pharmaceuticals has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Kobayashi Pharmaceuticals's sustainability data and climate commitments